diluran 250mg - search results

New Zealand - English - Medsafe (Medicines Safety Authority)

imuran

pharmacy retailing (nz) ltd t/a healthcare logistics - azathioprine 25mg - film coated tablet - 25 mg - active: azathioprine 25mg excipient: lactose monohydrate magnesium stearate maize starch opadry orange 06b230003 starch stearic acid - imuran is used as an immunosuppressant antimetabolite, either alone or, more commonly in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids.

Israel - English - Ministry of Health

edurant

j-c health care ltd - rilpivirine as hydrochloride - tablets - rilpivirine as hydrochloride 25 mg - rilpivirine - rilpivirine - edurant™, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-naïve adult patients with hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy.

European Union - English - EMA (European Medicines Agency)

edurant

janssen-cilag international n.v. - rilpivirine hydrochloride - hiv infections - antivirals for systemic use - edurant, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (hiv‑1) infection in antiretroviral treatment‑naïve patients 12 years of age and older with a viral load ≤ 100,000 hiv‑1 rna copies/ml. as with other antiretroviral medicinal products, genotypic resistance testing should guide the use of edurant.,

United States - English - NLM (National Library of Medicine)

edurant- rilpivirine hydrochloride tablet, film coated

janssen products, lp - rilpivirine hydrochloride (unii: 212wax8kdd) (rilpivirine - unii:fi96a8x663) - rilpivirine 25 mg - edurant, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-naïve patients 12 years of age and older and weighing at least 35 kg with plasma hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy. limitations of use: - more edurant treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure (hiv-1 rna ≥50 copies/ml) compared to edurant treated subjects with hiv-1 rna less than or equal to 100,000 copies/ml [see clinical studies (14.1)] . edurant is indicated in combination with vocabria (cabotegravir) for short-term treatment of hiv-1 infection in adults and adolescents 12 years and older and weighing at least 35 kg who are virologically suppressed (hiv-1 rna less than 50 copies/ml) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir